Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

HOPA 2018 | The importance of pharmacist intervention in the treatment of GvHD with ruxolitinib and ibrutinib

Katie Gatwood • 21 Mar 2018
HOPA 2018
General Ibrutinib Ruxolitinib

It is an exciting time in the field of graft versus host disease (GvHD) research, as new drugs for the treatment of this disease in post-transplant patients have been FDA approved or received breakthrough therapy designation. Such drugs include ruxolitinib and ibrutinib, and although these drugs have shown to be effective in treating patients with GvHD, there are still challenges that pharmacists must be aware of. Here, Katie Gatwood, PharmD, BCOP, of Vanderbilt University Medical Center, Nashville, TN, explains the challenges that come with this therapy and the importance of pharmacist intervention when using ruxolitinib or ibrutinib for the treatment of GvHD. This interview was recorded at the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO.

More from Katie Gatwood

1:09
Treating GvHD: current challenges and newly approved drugs
Katie Gatwood • 21 Mar 2018
2:29
Ruxolitinib and ibrutinib: the future for GvHD treatment?
Katie Gatwood • 21 Mar 2018

Related Videos

4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
1:41
The consequences of regulatory changes on access to devices and reagents needed for graft processing
Christian Chabannon • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals